Log In
Print
BCIQ
Print
Print this Print this
 

omarigliptin (MK-3102)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionOnce-weekly, oral dipeptidyl peptidase-4 (DPP-4; CD26) inhibitor
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today